Tai TA, Latimer NR, Benedict Á, Kiss Z, Nikolaou A. Prevalence of immature survival data for anti-cancer drugs presented to the National Institute for Health and Care Excellence and impact on decision making. Value Health. 2021;24(4):505–12.

Article  PubMed  Google Scholar 

Latimer NR. Survival analysis for economic evaluations alongside clinical trials: extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Mak. 2013;33(6):743–54.

Article  Google Scholar 

Bell Gorrod H, Kearns B, Stevens J, Thokala P, Labeit A, Latimer N, et al. A review of survival analysis methods used in NICE Technology Appraisals of cancer treatments: consistency, limitations, and areas for improvement. Med Decis Mak. 2019;39(8):899–909.

Article  Google Scholar 

Latimer NR, Adler AI. Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness. BMJ Med. 2022;1(1): e000094.

Article  PubMed  PubMed Central  Google Scholar 

Quinn C, Garrison LP, Pownell AK, Atkins MB, de Pouvourville G, Harrington K, et al. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. J Immunother Cancer. 2020;8(2): e000648.

Article  PubMed  PubMed Central  Google Scholar 

Palmer S, Borget I, Friede T, Husereau D, Karnon J, Kearns B, et al. A guide to selecting flexible survival models to inform economic evaluations of cancer immunotherapies. Value Health. 2023;26(2):185–92.

Article  PubMed  Google Scholar 

Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data (2013). Available from: https://www.sheffield.ac.uk/media/34225/download?attachment. Accessed June 2024.

Bullement A, Latimer NR, Bell GH. Survival extrapolation in cancer immunotherapy: a validation-based case study. Value Health. 2019;22(3):276–83.

Article  PubMed  Google Scholar 

Ouwens MJNM, Mukhopadhyay P, Zhang Y, Huang M, Latimer N, Briggs A. Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations. Pharmacoeconomics. 2019;37(9):1129–38.

Article  PubMed  PubMed Central  Google Scholar 

Klijn SL, Fenwick E, Kroep S, Johannesen K, Malcolm B, Kurt M, et al. What did time tell us? A comparison and retrospective validation of different survival extrapolation methods for immuno-oncologic therapy in advanced or metastatic renal cell carcinoma. Pharmacoeconomics. 2021;39(3):345–56.

Article  PubMed  Google Scholar 

Jin S, Pazdur R, Sridhara R. Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015. J Clin Oncol. 2017;35(33):3745–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stefaniak N, Walker J, Murphy ML, McKinney M, Liu L, Edge SB. Do eligibility criteria restrict access to clinical trials? J Clin Oncol. 2020;38(29_Suppl.):94–94.

Article  Google Scholar 

Rutherford M, Lambert P, Sweeting M, Pennington R, Crowther M, Abrams K, et al. NICE DSU Technical Support Document 21. Flexible methods for survival analysis. 2020. Available from: http://www.nicedsu.org.uk. Accessed 30 Aug 2024.

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janjigian YY, Shitara K, Moehler MH, Garrido M, Gallardo C, Shen L, et al. Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. J Clin Oncol. 2023;41(4_Suppl.):291–291.

Article  Google Scholar 

Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Institute for Health and Care Excellence (NICE). Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857). 2023. Available from: https://www.nice.org.uk/guidance/ta857. Accessed 30 Aug 2024.

Shitara K, Moehler MH, Ajani JA, Shen L, Garrido M, Gallardo C, et al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649. J Clin Oncol. 2024;42(3_Suppl.):306.

Article  Google Scholar 

National Cancer Registration and Analysis Service. CancerData. Available from: https://www.cancerdata.nhs.uk/. Accessed 3 Jul 2023.

Lambert PC, Royston P, Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. 2009. Available from: https://ageconsearch.umn.edu/record/127346. Accessed 3 Jul 2023.

Lambert PC. Modeling of the cure fraction in survival studies. Stata J Promot Commun Stat Stata. 2007;7(3):351–75.

Article  Google Scholar 

Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006;260(2):103–17.

Article  CAS  PubMed  Google Scholar 

Andersson TM, Dickman PW, Eloranta S, Lambert PC. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol. 2011;11(1):96.

Article  PubMed  PubMed Central  Google Scholar 

Latimer N, Rutherford M. Mixture and non-mixture cure models for health technology assessment: what you need to know. Pharmacoeconomics. 2024. https://doi.org/10.1007/s40273-024-01406-7.

Article  PubMed  PubMed Central  Google Scholar 

Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571.

Article  PubMed  Google Scholar 

Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100. J Clin Oncol. 2021;39(9):966–77.

Article  CAS  PubMed  Google Scholar 

Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71.

Article  CAS  PubMed  Google Scholar 

Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234–47.

Article  CAS  PubMed  Google Scholar 

Chau I, Norman AR, Cunningham D, Oates J, Hawkins R, Iveson T, et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma: individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol. 2009;20(5):885–91.

Article  CAS  PubMed  Google Scholar 

Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21.

Article  CAS  PubMed  Google Scholar 

Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.

Article  PubMed  Google Scholar 

Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AFC, Wotherspoon A, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, André T, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32(31):3520–6.

Article  CAS  PubMed  Google Scholar 

Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I, et al. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ann Oncol. 2015;26(10):2097–101.

Article